[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-418765-105":59,"doc-detail-418765-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-personal-perspective-of-patient-centred-clinical-trials","A personal perspective of patient-centred clinical trials","","Early phase trial participation is explored through the first-hand journey of three participants, focusing on tangible benefits, practical challenges, and needed patient-centric innovations. The discussion contrasts traditional emphasis on dose finding and toxicity with the growing importance of patient experience as trials expand in number and therapeutic intent. Reported benefits include access to novel therapies, support, and close monitoring, while challenges include eligibility constraints, financial burdens, and communication gaps. Solutions proposed emphasize trial navigators, improved communication training, and greater flexibility in enrolment criteria to widen trial access.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-personal-perspective-of-patient-centred-clinical-trials/418765/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-personal-perspective-of-patient-centred-clinical-trials/418765.png","ImageObject",300,407,{"name":92,"@type":93},"Taylor Morgan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the key objective of the article?","Question",{"text":112,"@type":113},"To describe the first-hand journey of three early phase trial participants and highlight the benefits, challenges, and patient-centric innovations needed to improve the trial experience.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are patient experiences in early phase clinical trials increasingly important?",{"text":117,"@type":113},"As early phase trials have expanded and shifted toward more targeted therapeutic intent, patient experience has become more critical to prioritizing study design.",{"name":119,"@type":110,"acceptedAnswer":120},"What benefits and challenges of participation are discussed?",{"text":121,"@type":113},"Benefits include access to novel therapies, support, and close monitoring, while challenges involve eligibility criteria, financial issues, and communication problems.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},418765,1791430455,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www.oncotarget.com](www.oncotarget.com) Oncotarget, 2025, Vol. 16, pp: 808-812  \nResearch Perspective  \nA personal perspective of patient-centred clinical trials  \nTrevor Tyne 1,*, Elizabeth Ivimey 1,*, Leanne Duggan 1,* and Jia Liu 1,2,3 1The Kinghorn Cancer Centre, St Vincent’s Hospital, Sydney, NSW, Australia  \n2School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia 3Garvan Institute of Medical Research, Sydney, NSW, Australia  \n*These authors contributed equally to this work Correspondence to: Jia Liu, email: [jia.liu@svha.org.au](jia.liu@svha.org.au)  \nKeywords: precision oncology; patient-centric care; clinical trials; tumor agnostic; drug development  \nReceived: October 13, 2025 Accepted: October 21, 2025 Published: November 14, 2025  \nCopyright: © 2025 Tyne et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nABSTRACT  \nKey objective: To illustrate the first-hand journey of three early phase trial participants highlighting their benefits and challenges of participation and patientcentric innovations required to improve trial experience.  \nKnowledge generated: Early phase trials have traditionally centred on dosefinding and toxicity. However as they have increased in number and improved in therapeutic intent, the patient experience becomes increasingly important. This article illustrates benefits of participation including access to novel therapies, support and close monitoring but challenges around eligibility criteria, finances, and communication. Proposed solutions including trial navigators, enhanced communication training, and greater flexibility in enrolment criteria to improve trials access.  \nINTRODUCTION  \nEarly phase clinical trials are crucial for advancing cancer therapeutics, yet the patient experience in these trials remains understudied. Traditionally EPCTs were reserved for patients with refractory/rare cancers where standard-of-care therapies are ineffective or no longer exist. However in more recent years, EPCTs are increasingly moving forwards in the treatment sequence for many settings particularly due to improvements in biomarker-matched therapies [1, 2], and initiatives such as FDA’s Project FrontRunner [3]. As such, understanding and prioritising the patient experience and perspective in biomarker-matched trials are critical to ensure these trials are conducted with the patient is at the centre of the study design is critical [4] . Tumor-agnostic trials provide a unique opportunity for patients with rare cancers harbouring biomarkers that inform therapeutic opportunities, to access genomically matched therapies. Although tumor-agonistic trials still represent a small number of EPCT opportunities and drug approvals, these approaches, often underpinned by biomarker-selection and molecular stratification, often result in higher response  \nrates >20% and more meaningful clinical benefit [5] . Here, we provide a first-hand account of the perspectives of three individuals who have participated in biomarker matched trials. Our journeys through these trials reveals both their promise and opportunities for improvement in trial conduct to ensure these are patient-centric.  \nTrevor’s story  \nMy journey into the realm of early-phase clinical trials has been marked by unexpected challenges and profound hope. Diagnosed with leiomyosarcoma, a rare and aggressive cancer, I faced significant hurdles due to its unpredictable nature. The initial years were fraught with misdiagnoses and a lack of clarity regarding available treatment options. Like many patients with rare cancers, accessing advanced treatments was challenging, as standard care options were either ineffective or posed risks incompatible with my pre-existing medical conditions.  \nA pivotal moment o","cbCaicclInJVpRHR","https://ap.wps.com/l/cbCaicclInJVpRHR","pdf",308347,"English","# Research Perspective\n## Abstract\n## Introduction\n## Trevor’s story\n## Beth’s story","[{\"question\":\"What is the key objective of the article?\",\"answer\":\"To describe the first-hand journey of three early phase trial participants and highlight the benefits, challenges, and patient-centric innovations needed to improve the trial experience.\"},{\"question\":\"Why are patient experiences in early phase clinical trials increasingly important?\",\"answer\":\"As early phase trials have expanded and shifted toward more targeted therapeutic intent, patient experience has become more critical to prioritizing study design.\"},{\"question\":\"What benefits and challenges of participation are discussed?\",\"answer\":\"Benefits include access to novel therapies, support, and close monitoring, while challenges involve eligibility criteria, financial issues, and communication problems.\"}]","A personal perspective of patient-centred clinical trials | PDF",1790614284,13]